Evidence map›Paper›PMID 40256636›Full record

ArticleRheumatology advances in practice2025

Machine learning

Fabian Proft, Janis L Vahldiek, Joeri Nicolaes, Rachel Tham, Bengt Hoepken, Baran Ufuktepe, Denis Poddubnyy, Keno K Bressem

2 registry-linked trialsAbstract read
In one paragraph

Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01087762 phase3completednot on this map

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

TypeinterventionalSponsorUCB BIOSCIENCES GmbHRan2010 to 2015Enrolled325ConditionsSpondyloarthropathiesArmsCZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
NCT02505542 phase3completednot on this map

A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo

TypeinterventionalSponsorUCB BIOSCIENCES GmbHRan2015 to 2019Enrolled736ConditionsAxial Spondyloarthrithis, Ankylosing SpondylitisArmsCertolizumab Pegol, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fabian ProftDepartment of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-4306-033X
Janis L VahldiekDepartment of Radiology, Universitätsmedizin Berlin, corporate member of Freie Charité - Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-1537-1424
Joeri NicolaesUCB Pharma, Brussels, Belgium.ORCID https://orcid.org/0000-0003-2789-8781
Rachel ThamUCB Pharma, Slough, UK.
Bengt HoepkenUCB Pharma, Monheim am Rhein, Germany.
Baran UfuktepeUCB Pharma, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-8909-4028
Denis PoddubnyyDepartment of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4537-6015
Keno K BressemDepartment of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-9249-8624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Diagnosis of axial spondyloarthritis (axSpA) is primarily established through the identification of the presence or absence of radiographic sacroiliitis. However, the reliability of conventional radiographs (X-rays) is undermined by significant interreader variability. A machine learning tool could reduce diagnosis time, thereby minimising interreader variability. The present study aimed to evaluate the performance of a deep learning model for detecting radiographic sacroiliitis in axSpA patients from the RAPID-axSpA (NCT01087762) and C-OPTIMISE (NCT02505542) trials. Methods: Radiographs from the RAPID-axSpA and C-OPTIMISE cohorts were retrospectively used. The deep learning model was previously trained by using a transfer learning approach on non-medical data. The model's agreement with expert readers was tested on baseline X-rays using central reader data. Sensitivity, specificity, Cohen's κ, positive and negative predictive values and the area under the receiver operating characteristics curve were calculated. Results: The model's performance was evaluated in the RAPID-axSpA ( Conclusions: The tested deep learning model exhibited accurate radiographic sacroiliitis detection in axSpA patients from diverse clinical trials. The proposed deep learning model could expedite diagnosis, reduce healthcare resource usage and improve patient care pathways.

Indexed as

artificial intelligenceaxial spondyloarthritisdeep learningmachine learningnon-radiographic axial spondyloarthritisradiographic axial spondylarthritis

Identifiers

PMID40256636
PMCPMC12007599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.